amarantus bioscience inc AMBS OTCBB - OTCQB

Amarantus BioSciences, Inc., a development stage biopharmaceutical drug development company, focuses on developing intellectual property and proprietary technology to develop drug candidates to treat human disease. Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) The company owns the intellectual property rights to a therapeutic protein, known as Mesencephalic-Astrocyte-derived Neurotrophic Factor. MANF is a protein that corrects protein misfolding. This property provides a rationale for the research and development of MANF-based products as therapeutics for human disease. Its MANF product development activity is centered on a therapy for Parkinson’s disease, and other apoptosis-related disorders. The company also owns an inventory of 88 cell lines that is referred to as PhenoGuard Cell Lines. History Amarantus BioSciences, Inc. was founded in 2008.